Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 GSK Licenses RA Drug from ChemoCentryx | Contract Pharma

What are you searching for?

Sign in
Breaking News

GSK Licenses RA Drug from ChemoCentryx

Pays $25 million for worldwide development and commercialization license

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

GlaxoSmithKline has exercised its option to obtain an exclusive worldwide license to further develop and commercialize ChemoCentryx’s investigational drug CCX354 for the treatment of rheumatoid arthritis (RA). ChemoCentryx recently reported positive results from a Phase II trial investigating the safety, tolerability, clinical and biological activity of CCX354 in patients with RA.

ChemoCentryx will receive an option exercise fee of $25 million and will be eligible for further regulatory and sales milestone payments, as well as royalties on sales. GSK will be solely responsible for funding further clinical development and commercialization for CCX354 worldwide.

“This announcement is a key milestone for ChemoCentryx that further validates our ability to advance new medicines from drug discovery through clinical development,” said Thomas J. Schall, Ph.D., president and chief executive officer of ChemoCentryx. “Furthermore, the exercise fee associated with this agreement provides additional financial flexibility to our already strong balance sheet. GSK’s global reach and financial commitment will be invaluable to the advancement of CCX354 through the rest of its development.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics